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erate decision making should lead to 
the adoption of standards that balance 
payment of patent licensing royalties 
with technological superiority. 
Through rigorous disclosure and 
licensing policies, SSOs also hope to 
avoid future lawsuits in which previ-
ously unknown patent owners make 
assertions of infringement against 
M
ost enGineeRinG-BAseD in-
dustries construct prod-
ucts from standard, well-
understood components. 
By contrast, despite the 
early attachment of the moniker “ge-
netic engineering” to biotechnology, 
standardization in the biological sci-
ences has been relatively rare. In 2004, 
MIT computer scientist Tom Knight of-
fered this colorful characterization of 
the difference between a biologist and 
an engineer: “A biologist goes into the 
lab, studies a system, and finds that it 
is far more complex than anyone sus-
pected. He’s delighted; he can spend 
a lot of time exploring that complexity 
and writing papers. An engineer goes 
into the lab and makes the same find-
ing. His response is ‘How can I get rid 
of this?’”2
Knight’s insightful observation not-
withstanding, efforts are currently be-
ing made to standardize biology. What 
lessons (if any) can biology learn from 
engineering?
standard-setting organizations
The area of engineering where stan-
dard setting has been most discussed 
is information and communication 
technology (ICT). In the ICT industries, 
standards often have the potential to 
read on dozens if not hundreds of pat-
ents. Thus standard-setting organiza-
tions (SSOs) that make choices among 
potential standards generally have pol-
icies concerning patent disclosure and 
licensing. The most elaborate policies 
require disclosure of patents not only 
by those entities that actually submit 
technology to the standard but also 
by other members of the standards 
organization. As for licensing, patent 
owners may be required to license 
royalty-free or, more frequently, on 
“reasonable and nondiscriminatory 
terms.” At least in theory, such delib-
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which emerged from academic insti-
tutions, do not appear to have adopted 
formal policies on patents. But in the 
case of data standards, the administra-
tive costs associated with establishing 
an SSO-type apparatus may exceed any 
challenges that patents pose. At least 
at this stage, the numbers of patents 
that could be asserted may not be par-
ticularly large.  
Biomarker standards
Another important category of biologi-
cal standardization efforts involves 
biomarkers. Biomarkers are biological 
signs of drug toxicity and efficacy, and 
the pharmaceutical industry has high 
hopes that improved biomarkers will 
yield expedited preclinical drug safety 
evaluation as well as early indicators of 
clinical safety and efficacy. With such 
indicators, firms should be able to re-
duce the costly drug trial failures that 
are currently a major contributing fac-
tor to diminished biopharmaceutical 
innovation. 
Pharmaceutical companies have 
formed a number of consortia that 
pool information and conduct collab-
orative research to identify consensus 
biomarker standards. Prominent con-
sortia include the Predictive Safety 
Testing Consortium (PSTC), which 
comprises 17 major multinational 
pharmaceutical firms. The PSTC has 
already been successful in securing 
U.S. Food and Drug Administration 
and European Medicines Evaluation 
Agency approval for seven new bio-
markers that signal kidney injury at 
the preclinical stage.   
The various biomarker standards 
consortia set up by pharmaceutical 
firms deal very explicitly with patent 
rights. To some extent, these consortia 
adopt policies similar to those of SSOs 
in the ICT industries. For example, al-
though the PSTC policy does not ad-
dress the licensing of “background” 
patents that firms may bring to the col-
laborative research, it addresses with 
great care future patents on biomarker 
standards that may emerge. Specifi-
cally, PSTC members assign any future 
patent rights to a non-profit trusted in-
termediary, Critical Path. Critical Path, 
in turn, is obliged to license the rights 
on “fair, neutral, and commercially 
reasonable” terms to members of the 
Consortium as well as third parties. 
Described another way, in the PSTC, 
future patents are addressed in terms 
somewhat similar to those used by ICT 
SSOs for background patents. 
The emerging discipline of synthet-
ic biology aims for what is arguably 
the most comprehensive form of stan-
dardization. It hopes to make all of 
biotechnology a science that relies on 
standardized, well-characterized DNA 
“parts.” These parts could then be as-
sembled into composite devices and 
systems with similarly well-defined be-
havior. When transplanted into suit-
able model organism “chassis” (which 
had themselves been standardized), 
the composite systems could yield 
outputs ranging from drug therapies 
to environmentally friendly fuels. 
Standards would cover not only parts 
and chassis but, perhaps even more 
importantly, the interfaces used to as-
semble parts and the interactions be-
tween parts and host cells.  
standardization in 
synthetic Biology
The synthetic biology community is 
still debating precisely how much 
information about a biological stan-
dard is necessary before full stan-
dardization can be said to have been 
achieved.1 Even so, some progress has 
been made. The Registry of Standard 
Biological Parts (http://www.partsreg-
istry.org), an academic effort that 
receives significant federal funding, 
now contains about 3,200 parts. Each 
of these parts adheres to the so-called 
BioBricks protocol for cloning and 
physical linking and has specific as-
product manufacturers that use a 
widely adopted standard. In such cir-
cumstances, the patent holder could 
arguably extract a royalty in excess of 
the technical contribution made by 
the patent. 
How applicable are the approaches 
adopted by SSOs in the ICT industries 
to biological standards? To a signifi-
cant extent, the answer depends on 
the type of standard. 
Currently, some of the most ad-
vanced standardization efforts involve 
specifications for the development 
and presentation of biological data. 
The Microarray Gene Expression Data 
Society (MGED) was an early leader 
in the field. MGED’s “Minimum In-
formation About a Microarray Experi-
ment” (MIAME) standard has inspired 
similar efforts in many other biologi-
cal fields, including proteomics, me-
tabolomics, and RNA interference.4 
The Minimum Information for Bio-
logical and Biomedical Investigations 
(MIBBI) project takes standardization 
one step further by attempting to ratio-
nalize the varying data standards that 
have developed in different biological 
fields. MIBBI’s goal is interoperability 
across data sets from different biologi-
cal communities.5
These data standardization efforts, 
some of the 
most advanced 
standardization  
efforts involve 
specifications for  
the development  
and presentation  
of biological data.
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sociated inputs and outputs. 
The Registry of Standard Biological 
Parts presents what may be the most 
interesting, and difficult, challenge 
for patents on biological standards. As 
currently constituted, the Registry may 
well read on a large number of patents. 
Tens of thousands of U.S. patents have 
been granted on DNA sequences. Al-
though these patents are not specific 
to synthetic biology, they could certain-
ly read on various standardized parts. 
Preliminary patent mapping also re-
veals a significant number of patents 
highly relevant to synthetic biology in 
particular.3 
Thus far the Registry essentially 
puts results in the public domain, al-
beit with a hortatory suggestion that 
users should contribute back infor-
mation and data, so as to improve the 
“community resource.” As for back-
ground patents that the Registry may 
infringe, the academic scientists in-
volved appear to be proceeding under 
the assumption that they will be not 
be sued because potential plaintiffs 
will not foresee significant monetary 
payoffs from such suits. As for poten-
tial industry defendants, at this stage it 
does not appear that Registry parts are 
being used by industry to make com-
mercially valuable products.
At some point, however, Registry 
parts may begin to be used by industry. 
In addition, use of such standardized 
parts may be difficult to conceal. Thus 
one apparently common biopharma-
ceutical industry strategy for avoiding 
patents on research inputs—secret 
infringement—may not be possible.6 
Industry users that are contemplating 
using Registry parts might therefore 
consider organizing patent mapping 
efforts to determine whether patents 
do in fact read on key standards. 
The situation the Registry faces ar-
guably bears some similarity to that 
faced by standards developers for the 
Web in its early days. For example, 
in the case of the XML standard for 
structured data presentation, the criti-
cal early work was done by develop-
ers from academic and commercial 
organizations, as well as independent 
contributors, without any significant 
thought being given to patents. 
As the Web matured, however, 
the issue of background patents on 
core technical standards had to be 
addressed. By 1999, the World Wide 
Web Consortium had created a patent 
policy working group. Participants in 
that group included representatives 
from the major software, hardware, 
and telecommunications firms (Apple, 
AT&T, Hewlett-Packard, IBM, Intel, 
Motorola, Nokia, Nortel, Sun Micro-
systems, and Xerox).
conclusion
At this stage in the evolution of syn-
thetic biology, it is probably too early 
to determine whether any of the work 
done thus far has yielded key stan-
dards upon which the community will 
eventually converge. But as synthetic 
biologists and other biologists con-
tinue work on standardization, they 
should carefully examine mechanisms 
(both successful and unsuccessful) 
for addressing patent issues that have 
been invoked in the ICT industries. 
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